GILD earnings call for the period ending June 30, 2021.
Compare GILD Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Gilead Sciences
And there's a good chance you could be earning even more than that.
The battle for market share could come down to which drug has the lesser side effects.
Despite strong headwinds, there may be hope for this biotech.
Gilead Sciences' revenues are being boosted by its COVID-19 treatment, but it will still be a good investment in a post-pandemic world.
They pay more than double what you'd earn with the average stock in the S&P 500.
With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story.
GILD earnings call for the period ending March 31, 2021.
Gilead Sciences had a stellar 2020, but this year is looking a little more perilous.
Too bad there are issues with side effects.